Nashwa Ahmed

Theon Therapeutics is a biotechnology company focused on developing first-in-class small molecule therapies for the treatment of cancer. The company's primary research centers on modulating the tumor microenvironment to overcome resistance to existing immunotherapies, such as checkpoint inhibitors. Their lead program targets the P2X7 receptor, a key mediator of purinergic signaling that plays a significant role in immune suppression within tumors. Founded by Dr. Nashwa Ahmed, a former venture capitalist with extensive experience in life sciences, Theon Therapeutics aims to deliver oral, effective treatments for patients with various solid tumors. The company is headquartered in South San Francisco and is backed by prominent life science investors.